News Bayer's regorafenib kicks off brain cancer platform trial Bayer has become the first pharma company to take part in a new platform trial designed to find new treatments for brain cancer.
News FDA declines to approve AbbVie's Botox follow-up AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
